by Site Strategics | May 11, 2023 | News
In compliance with NIAID/NIH guidelines research at MiraVista Diagnostics utilizing synthetic or recombinant DNA is annually reviewed by the MiraVista Institutional Biosafety Committee (IBC). The IBC is made up of internal and external subject matter experts to ensure...
by Site Strategics | Feb 10, 2023 | News
MiraVista Diagnostics’ article “Pulmonary Histoplasmosis: A Clinical Update” has been published in “Journal of Fungi” as part of the Special Issue “Diagnosis and Treatment of Invasive Pulmonary Fungal Infections.” Read the...
by Site Strategics | Feb 10, 2023 | News
MIRAVISTA DIAGNOSTICS WILL BE AT THIS EVENT The American Transplant Congress (ATC) brings together the people and organizations who are redefining the transplant industry. See us at booth 525. (https://www.atcmeeting.org/)
by Site Strategics | Feb 9, 2023 | News
MIRAVISTA DIAGNOSTICS WILL BE AT THIS EVENT The 68th Annual Coccidioidomycosis Study Group will take place April 5th-April 6th, 2024 in San Antonio, Texas. It will be hosted at The Menger Hotel. (https://coccistudygroup.org/68th-annual-meeting/)
by Site Strategics | Feb 9, 2023 | News
MIRAVISTA DIAGNOSTICS WILL BE AT THIS EVENT ATS 2024 showcases the latest advances and discoveries in respiratory science, patient care and global respiratory health. See us at booth 1431. (https://conference.thoracic.org/)
by Site Strategics | Oct 14, 2021 | News
The second US based multicenter study found high concordance with the MiraVista LFA and EIA and reported higher sensitivity with the EIA. Read more about the US LFA Multicenter Study.